CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 107 enrolled
Drug / intervention
BMS-955176 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01803074
NCT01803074Phase 2Completed
CompareCT.gov

Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects

ViiV Healthcare·interventional·Posted Mar 4, 2013·Updated Nov 25, 2019

In Brief

A Phase 2 clinical trial evaluating BMS-955176, Placebo matching with BMS-955176, and 4 other interventions for Infection, Human Immunodeficiency Virus and HIV Infections. Completed, enrolled 107 participants across 1 site.

Detailed Summary

The primary purpose of this study is to study the safety and tolerability of a HIV drug and to evaluate a decrease of HIV-1 virus level in blood after treatments in HIV-1 infected patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfection, Human Immunodeficiency Virus, HIV Infections
CountriesGermany
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMar 4, 2013
Enrollment StartApr 4, 2013
Primary CompletionNov 29, 2014
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 13.3 years ago

Interventions

BMS-955176drug

BMS-955176

Placebo matching with BMS-955176drug

Placebo matching with BMS-955176

Atazanavirdrug

Atazanavir

Ritonavirdrug

Ritonavir

Tenofovirdrug

Tenofovir

Emtricitabinedrug

Emtricitabine